See more : Thermo Fisher Scientific Inc. (TN8.DE) Income Statement Analysis – Financial Results
Complete financial analysis of GRI Bio, Inc. (GRI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRI Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Applied Biosciences Corp. (APPB) Income Statement Analysis – Financial Results
- Pernod Ricard SA (PDRDF) Income Statement Analysis – Financial Results
- Impex Ferro Tech Limited (IMPEXFERRO.NS) Income Statement Analysis – Financial Results
- VAT Group AG (VACNY) Income Statement Analysis – Financial Results
- Heiwa Real Estate Co., Ltd. (8803.T) Income Statement Analysis – Financial Results
GRI Bio, Inc. (GRI)
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 21.77M | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Cost of Revenue | 57.00K | 206.00K | 73.00K | 0.00 | 735.00 | 612.00 |
| Gross Profit | 21.71M | -206.00K | -73.00K | 100.00K | -735.00 | -612.00 |
| Gross Profit Ratio | 99.74% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.23M | 242.00K | 249.00K | 3.71M | 1.88M | 3.51M |
| General & Administrative | 1.49M | 2.00M | 813.00K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.10M | 2.00M | 813.00K | 1.11M | 1.27M | 800.08K |
| Other Expenses | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.33M | 2.24M | 1.06M | 4.81M | 3.15M | 4.31M |
| Cost & Expenses | 11.39M | 2.24M | 1.06M | 4.89M | 3.15M | 4.31M |
| Interest Income | 0.00 | 26.00K | 0.00 | 0.00 | 0.00 | 1.06K |
| Interest Expense | 2.08M | 653.00K | 547.00K | 34.00K | 197.03K | 0.00 |
| Depreciation & Amortization | 57.00K | 50.00K | 73.00K | 75.00K | 735.00 | 612.00 |
| EBITDA | -10.90M | -2.51M | -9.21M | -4.71M | -3.27M | -4.31M |
| EBITDA Ratio | -50.07% | 0.00% | 0.00% | -4,713.00% | 0.00% | 0.00% |
| Operating Income | -11.39M | -2.24M | -1.06M | -4.79M | -3.15M | -4.31M |
| Operating Income Ratio | -52.31% | 0.00% | 0.00% | -4,788.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -978.00K | -8.24M | -34.00K | -310.07K | 1.06K |
| Income Before Tax | -13.04M | -3.22M | -1.56M | -4.82M | -3.46M | -4.31M |
| Income Before Tax Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.77M | 325.00K | -50.00K | -131.30K | 5.00 | -2.00 |
| Net Income | -13.04M | -3.54M | -1.51M | -4.82M | -3.46M | -4.31M |
| Net Income Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| EPS | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| EPS Diluted | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| Weighted Avg Shares Out | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
| Weighted Avg Shares Out (Dil) | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Source: https://incomestatements.info
Category: Stock Reports